within Pharmacolibrary.Drugs.ATC.J;

model J01FA08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.35,
    Cl             = 20 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Troleandomycin is a macrolide antibiotic, structurally related to erythromycin. It was formerly used for the treatment of infections caused by susceptible bacteria and also investigated for use in asthma and for steroid-sparing effects. Troleandomycin is currently not widely used in clinical practice and is not approved in many countries.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for a typical adult, as there is no published pharmacokinetic study available with detailed compartmental analysis.</p><h4>References</h4><ol><li><p>Wang, JS, Wang, W, Xie, HG, Huang, SL, &amp; Zhou, HH (1997). Effect of troleandomycin on the pharmacokinetics of imipramine in Chinese: the role of CYP3A. <i>British journal of clinical pharmacology</i> 44(2) 195–198. DOI:<a href=&quot;https://doi.org/10.1046/j.1365-2125.1997.00649.x&quot;>10.1046/j.1365-2125.1997.00649.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9278210/&quot;>https://pubmed.ncbi.nlm.nih.gov/9278210</a></p></li><li><p>Rodvold, KA (1999). Clinical pharmacokinetics of clarithromycin. <i>Clinical pharmacokinetics</i> 37(5) 385–398. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199937050-00003&quot;>10.2165/00003088-199937050-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10589373/&quot;>https://pubmed.ncbi.nlm.nih.gov/10589373</a></p></li><li><p>Periti, P, Mazzei, T, Mini, E, &amp; Novelli, A (1992). Pharmacokinetic drug interactions of macrolides. <i>Clinical pharmacokinetics</i> 23(2) 106–131. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199223020-00004&quot;>10.2165/00003088-199223020-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1511528/&quot;>https://pubmed.ncbi.nlm.nih.gov/1511528</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01FA08;
